Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Sponsor
Emory University
Study ID
NCT01131039
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
FEMALE
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gemcitabine/Bevacizumab — DRUG
    Gemcitabine: IV, days 1,8, and every 21 days Bevacizumab: IV, day 1 and every 21 days until disease progression

Study Details

The purpose of the study is to determine whether the administration of bevacizumab and gemcitabine given by IV infusion can prolong survival, delay tumor growth, and/or shrink tumors in patients with ovarian cancer, primary peritoneal, or fallopian tube cancer.

Key Dates

First listed
May 26, 2010
Start date
Jan 31, 2011
Status verified
Dec 2013
Primary completion
Sep 30, 2011
Completion
Sep 30, 2011

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single

Primary Outcome Measure

Progression-free survival [ Time Frame: 2 years ]

Related Studies